Lessons In Leadership And Biotech Growth From Rallybio CEO Martin Mackay
Executive Summary
Veteran pharma leader Martin Mackay, CEO of Rallybio, recently spoke with In Vivo about building a new company on the cusp of retirement, what drives him, how he leads and what he is excited about in the company’s pipeline.
You may also be interested in...
Rallybio Looks To Deals To Grow ‘Transformative’ Rare Disease Pipeline
Emerging Company Profile: Armed with the insight of its ex-Alexion leaders, Rallybio is eyeing a spate of deals to develop and commercialize transformative drugs for rare diseases.
Rallybio Leverages Founders’ Experience, $145m In New Cash For Rare Diseases
Former Alexion execs and Rallybio co-founders Martin Mackay, Steve Uden and Jeffrey Fryer closed a series B venture capital round to take three candidates into the clinic and acquire additional programs.
Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio
Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.